Skip to search formSkip to main contentSkip to account menu

ozanimod

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

IndansOxadiazoles

Narrower (1)

RPC1063

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Neue Daten untermauern Wirksamkeit von Ozanimod bei MS
Bei Patienten mit schubförmiger MS hat sich der Sphingosin-1-Phosphat(S1P)-Rezeptoragonist Ozanimod in den beiden Phase-III… 
2019
2019
Ozanimod in Multiple Sclerosis
<p /> 
2019
2019
Neue Daten untermauern Wirksamkeit von Ozanimod bei MS
  • T. Heim
  • DNP - Der Neurologe & Psychiater
  • 2019
  • Corpus ID: 199370148
— Bei Patienten mit schubförmiger MS hat sich der Sphingosin-1-Phosphat(S1P)-Rezeptoragonist Ozanimod in den beiden Phase-III… 
2018
2018
Ozanimod, an Oral S1P Receptor Modulator, Is Effective and Well-Tolerated in the Long-Term Treatment of Moderate to Severe Ulcerative Colitis: P-012
2017
2017
Crystal forms of ozanimod and preparation method therefor
Provided are crystal forms of Ozanimod and a preparation method therefor. The provided crystal forms of Ozanimod comprise a… 
2017
2017
PD-010 Histological Remission Induced by Ozanimod is Associated with Clinical Remission and Endoscopic Mucosal Healing: Results from the TOUCHSTONE Study
Background: TOUCHSTONE was a randomized, double-blind, placebo-controlled phase 2 trial designed to assess the efficacy and… 
2017
2017
Crystal form of ozanimod, crystal form of hydrochloride thereof, and preparation method therefor
Disclosed are a crystal form of ozanimod, a crystal form of a hydrochloride thereof, and a preparation method therefor. The… 
2017
2017
Actualités thérapeutiques dans les MICI
RésuméLes anti-TNF sont utilisés depuis près de 20 ans dans les maladies inflammatoires chroniques intestinales (MICI) et en ont… 
2016
2016
Safety and Efficacy of Long-Term Treatment with Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Touchstone Extension: 571
2015
2015
A Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Results of the Maintenance Period of the TOUCHSTONE Study…